Regulation · United Kingdom

Are peptides legal
in the UK?

UK law asks two questions about a peptide: how is it presented, and what does it do in the body? Here are the rules, the MHRA’s 2026 position and the drug laws that apply.

Short answerRegulation · 6 min read · Updated 17 Nov 2026

It depends on how the peptide is presented and used. Under the Human Medicines Regulations 2012, a peptide presented as treating disease, or used to modify a body function by a pharmacological action, is a medicinal product and cannot be sold or supplied without authorisation. The MHRA has said it disregards “research purposes” claims used to avoid medicines law.

Key takeaways

  • A product is a medicinal product if it is presented as treating or preventing disease, or used to modify a physiological function by a pharmacological action; unauthorised medicinal products may not be sold or supplied.
  • The MHRA has said it disregards “research purposes” claims used to avoid medicines regulations, and judges presentation across labels, websites, social media and reviews.
  • BPC-157 and TB-500 are not controlled drugs; growth hormone and HCG are Class C, with possession excepted in Great Britain but supply prohibited.
  • The MHRA said in July 2026 that anyone selling retatrutide in the UK is doing so illegally.
  • In sport, BPC-157 (S0) and TB-500 (S2) are prohibited at all times.

01The test: is it a medicinal product?

UK medicines law does not list peptides by name. It asks whether a product is a medicinal product.

Regulation 2 of the Human Medicines Regulations 2012 gives two routes in. A product is medicinal if it is (a) “presented as having properties of preventing or treating disease in human beings”, or (b) a substance that “may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action, or making a medical diagnosis”. MHRA guidance adds that “disease” in the Regulations “includes any injury, ailment or adverse condition, whether of body or mind”.

Regulation 46 then says: “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.” There are narrow exceptions. The main one, regulation 167, covers “specials”: unlicensed products made to the specification of a doctor or other prescriber, supplied in response to an “unsolicited order” (the Regulations’ term), for the special needs of a patient that prescriber is directly responsible for, with no advertising of the product by anyone.

How the MHRA decides. Its borderline-products guidance (last updated 2 July 2026) says the MHRA weighs the properties of the ingredients, the product’s primary purpose and how consumers would use it, whether similar licensed products exist, and “how it is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews”.

02What the MHRA has said about peptides

In March 2026 the MHRA’s head of borderlines, Lynda Scammell, gave STV News a statement on peptides. “We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations,” it said. Where promotional material shows products are “in fact unauthorised medicines”, the MHRA said it takes action, “including the removal of the product from the UK market where necessary”.

Under regulation 2, a substance can also be a medicinal product because of what it does in the body, and the MHRA decides borderline cases product by product.

In April 2026 Aesthetics Journal, reporting a Guardian investigation, said the MHRA had opened an investigation into UK clinics making medicinal claims about peptides; the clinic claims The Guardian examined included BPC-157. The same report quoted an MHRA spokesperson: it “will take action against clinics which are identified as breaching the legal requirements.” We found no published outcome as of 17 Nov 2026.

Enforcement in 2026. On 28 May 2026 MHRA officers raided an estate near Northampton in what the agency called its largest ever seizure of unlicensed weight-loss medicines: about 12,000 doses, from a site believed to make and distribute “unlicensed weight loss medicines, including retatrutide and tirzepatide, as well as peptide products”. On 24 July the MHRA said retatrutide “has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.”

03Controlled drugs: growth hormone and HCG

The peptides usually sold as research chemicals, such as BPC-157 and TB-500, are not named as controlled drugs in Schedule 2 to the Misuse of Drugs Act 1971. A small group of hormones is. Part III of Schedule 2 lists as Class C: chorionic gonadotrophin (HCG), non-human chorionic gonadotrophin, somatotropin, somatrem and somatropin, the last three being forms of growth hormone. The same entry also lists clenbuterol, zeranol and zilpaterol, which are not peptides.

These hormones sit in Part II of Schedule 4 to the Misuse of Drugs Regulations 2001. In England, Wales and Scotland, regulation 4 disapplies the possession offence for them. Producing and supplying them without lawful authority remain prohibited under the 1971 Act. Northern Ireland has its own regulations, which this page does not cover.

04The Psychoactive Substances Act 2016

The Psychoactive Substances Act 2016 targets “psychoactive substances”: substances that, “by stimulating or depressing the person’s central nervous system”, affect a person’s “mental functioning or emotional state”. Controlled drugs and medicinal products are exempted substances under Schedule 1.

We have not found a published case applying the 2016 Act to a peptide. Whether it applies to a particular compound is a question for a lawyer, not for this page.

05Sport

Sport has its own rulebook, and it applies in the UK as everywhere else. WADA’s current Prohibited List names BPC-157 in class S0, non-approved substances, prohibited at all times. It lists “Thymosin-β4 and its derivatives e.g. TB-500” under S2.3, growth factors. UK medicines law has no bearing on either listing. Detail: peptides and anti-doping.

06UK at a glance

The questions people ask most, answered from the documents above.

QuestionShort answerWhere it comes from
Can a peptide be sold for use in people without UK authorisation?Not if it is a medicinal product, apart from narrow exceptions such as specials.Human Medicines Regulations 2012, regs 2, 46, 167
Does a “research purposes” label change that?Not if the claim is used to avoid medicines rules, the MHRA says.MHRA statement to STV News, Mar 2026
Is BPC-157 a controlled drug?No. It is not named in the Misuse of Drugs Act.Misuse of Drugs Act 1971, Sch 2
Is growth hormone controlled?Yes, Class C. In Great Britain possession is not an offence; supply without authority is prohibited.Misuse of Drugs Act 1971; Misuse of Drugs Regulations 2001, reg 4
Is retatrutide authorised?No. The MHRA says anyone selling it is doing so illegally.MHRA, 24 Jul 2026
Is BPC-157 allowed in sport?No. WADA class S0, at all times.WADA Prohibited List

07What we don’t know

The outcome of the MHRA’s clinic investigation. Nothing published as of 17 Nov 2026.

How the MHRA would classify a given peptide by function alone. Borderline decisions are made product by product. We have not found a published MHRA determination on BPC-157 or TB-500 specifically.

Northern Ireland. Controlled-drug rules there sit in separate regulations we have not summarised.

Changes to UK rules are logged in our regulatory changelog. For the other markets, see the US and Australia, or the overview.

This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.

RefSources

  1. The Human Medicines Regulations 2012 (SI 2012/1916), regulations 2, 46 and 167. UK legislation, revised text. www.legislation.gov.uk/uksi/2012/1916/contents
  2. MHRA. Borderline products: how to tell if your product is a medicine. Guidance, updated 2 Jul 2026. www.gov.uk/guidance/borderline-products-how-to-tell-if-your-…
  3. Misuse of Drugs Act 1971, Schedule 2, Part III (Class C drugs). UK legislation, revised text. www.legislation.gov.uk/ukpga/1971/38/schedule/2
  4. The Misuse of Drugs Regulations 2001 (SI 2001/3998), regulation 4 and Schedule 4, Part II. UK legislation (England, Wales and Scotland), revised text. www.legislation.gov.uk/uksi/2001/3998/regulation/4
  5. Psychoactive Substances Act 2016, section 2 and Schedule 1. UK legislation, revised text. www.legislation.gov.uk/ukpga/2016/2/contents
  6. MHRA. Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines. Press release, 29 May 2026. www.gov.uk/government/news/two-arrested-during-the-mhras-lar…
  7. MHRA. No summer shortcut for safe weight loss. Press release, 24 Jul 2026. www.gov.uk/government/news/no-summer-shortcut-for-safe-weigh…
  8. World Anti-Doping Agency. The Prohibited List: S0 Non-approved substances and S2.3 Growth factors. Current List, checked 17 Nov 2026. www.wada-ama.org/en/prohibited-list
  9. Flett A. The peptide boom: legal ‘loophole’ fuels rise of unregulated injectables (MHRA statement, Lynda Scammell). STV News, 19 Mar 2026. Press report of an MHRA statement. news.stv.tv/scotland/the-peptide-boom-call-for-review-of-leg…
  10. Aesthetics Journal. MHRA investigates clinics following peptide claims (reporting The Guardian). Trade press, 15 Apr 2026. Press report. aestheticsjournal.com/news/mhra-investigates-clinics-followi…

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

Is BPC-157 legal in the UK?

It is not a controlled drug, and it has no UK marketing authorisation. Selling or supplying it as a medicinal product breaches the Human Medicines Regulations 2012, and the MHRA has said it disregards “research purposes” claims used to avoid that.

Are peptides controlled drugs in the UK?

BPC-157 and TB-500 are not named in the Misuse of Drugs Act 1971. Growth hormone and HCG are Class C. Separately, a peptide that is a medicinal product may not be sold or supplied without authorisation under the Human Medicines Regulations 2012.

Can UK clinics offer unlicensed peptides?

Only within the narrow rules for unlicensed medicines, such as specials made to a prescriber’s specification for an individual patient, with no advertising. The MHRA opened an investigation into peptide clinics’ medicinal claims in 2026, according to press reports.

Does the US HHS peptide policy change anything in the UK?

No. It is a US enforcement policy for US compounding pharmacies. UK medicines law is separate.

Who enforces these rules?

The MHRA enforces medicines law, including through its Criminal Enforcement Unit, which carried out raids with police support in 2026. In sport, the WADA Prohibited List applies.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Every batch has a public lab report. Look it up by the batch number on the vial. Batch COA lookup